The DOI matches its Crossref record.
Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 22‐Year Follow‐Up Study and Response to a Booster Dose
Abstract
BACKGROUND: The duration of protection in children and adults (including health care workers) resulting from the hepatitis B vaccine primary series is unknown. METHODS: To determine the protection afforded by hepatitis B vaccine, Alaska Native persons who had received plasma-derived hepatitis B vaccine when they were >6 months of age were tested for antibody to hepatitis B surface antigen (anti-HBs) 22 years later. Those with levels <10 mIU/mL received 1 dose of recombinant hepatitis B vaccine and were evaluated on the basis of anti-HBs measurements at 10-14 days, 30-60 days, and 1 year. RESULTS: Of 493 participants, 60% (298) had an anti-HBs level >or=10 mIU/mL. A booster dose was administered to 164 persons, and 77% responded with an anti-HBs level >or=10 mIU/mL at 10-14 days, reaching 81% by 60 days. Response to a booster dose was positively correlated with younger age, peak anti-HBs response after primary vaccination, and the presence of detectable anti-HBs before boosting. Considering persons with an anti-HBs level >or=10 mIU/mL at 22 years and those who responded to the booster dose, protection was demonstrated in 87% of the participants. No new acute or chronic hepatitis B virus infections were identified. CONCLUSIONS: The protection afforded by primary immunization with plasma-derived hepatitis B vaccine during childhood and adulthood lasts at least 22 years. Booster doses are not needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Trépo, C., Chan, H. L. Y., & Lok, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60220-8 · Cited by 1,623
The Prevalence of Hepatitis B Virus Infection in the United States in the Era of Vaccination
Wasley, A., Kruszon‐Moran, D., Kuhnert, W., Simard, E. P., Finelli, L., McQuillan, G., & Bell, B. (2010) · The Journal of Infectious Diseases · doi:10.1086/653622 · Cited by 351
Self-citationBruce, M. G., Bruden, D., Hurlburt, D., Zanis, C., Thompson, G., Rea, L., Toomey, M., Townshend-Bulson, L., Rudolph, K., Bulkow, L., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv748 · Cited by 322
Self-citationLong-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer
Chang, M.-H., You, S.-L., Chen, C.-J., Liu, C.-J., Lai, M.-W., Wu, T.-C., Wu, S.-F., Lee, C.-M., Yang, S.-S., Chu, H.-C., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.05.048 · Cited by 258
Seroprotection after recombinant hepatitis B vaccination among newborn infants: A review
Schillie, S. F., & Murphy, T. V. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.12.012 · Cited by 105
Metadata
- Authors
- McMahon, B. J., Dentinger, C. M., Bruden, D., Zanis, C., Peters, H., Hurlburt, D., Bulkow, L., Fiore, A. E., Bell, B. P., & Hennessy, T. W.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11
- Volume
- 200
- Issue
- 9
- Pages
- 1390-1396
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2166475489
- Cited by
- 246
- References
- 0
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 22‐Year Follow‐Up Study and Response to a Booster Dose. https://app.cochat.ai/papers/10.1086/606119
- The paper
- McMahon, B. J., Dentinger, C. M., Bruden, D., Zanis, C., Peters, H., Hurlburt, D., Bulkow, L., Fiore, A. E., Bell, B. P., & Hennessy, T. W. (2009). Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 22‐Year Follow‐Up Study and Response to a Booster Dose. The Journal of Infectious Diseases. https://doi.org/10.1086/606119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.